External application of static magnetic fields (SMF), utilized specifically for the treatment of inflammatory conditions such as soft tissue injuries, has recently become popular as a complementary and/or alternative therapy with minimal investigation into efficacy or mechanism. Localized inflammation was induced via injection of inflammatory agentscarrageenan (CA) or histamine into rat hindpaws, alone or in conjunction with pharmacologic agents, resulting in a spatially and temporally defined inflammatory reaction. Application of a 10mT or 70mT, but not a 400mT, SMF for 15 or 30 minutes immediately following histamineinduced edema resulted in a significant, 20-50% reduction in edema formation. Additionally, a 2 hour, 70mT field application to CA-induced edema also resulted in significant (33-37%) edema reduction. Field application before injection or at the time of maximal edema did not influence edema formation or resolution, respectively. Together these results suggest the existence of a therapeutic threshold of SMF strength (below 400mT) and a temporal dependence of efficacy.
INTRODUCTION
External application of static magnetic fields, utilized specifically for the treatment of inflammatory conditions such as soft tissue injuries, has recently become popular as a complementary and/or alternative therapy with minimal investigation into efficacy or mechanism. While the literature supports a potential therapeutic benefit of pulsed electromagnetic field (PEMF) application to aid in the treatment of non-union bone fractures (2; 17) and osteoarthritis (5) , the acceleration of wound healing (4;32;41) and the modulation of angiogenesis (14;42) , direct evidence supporting the therapeutic use of static magnetic fields (SMF) is less established. Static magnetic fields are of particular interest as they are the primary field utilized in many of the over the counter products presently on the market, with approximately 5 billion dollars worldwide and 500 million dollars in the U.S. per annum being spent on magnetic field therapy (10) .
Recent studies have demonstrated that localized SMF application can modulate microvascular tone in skeletal muscle (26) and cutaneous tissue (27;28) whereas global SMF application can modulate both blood pressure (29) and flow (21;46) both suggesting that SMF application may be effective in treating edematous tissue conditions. Clinical investigation of local, chronic SMF treatment on post-lipectomy patients revealed significant reduction of edema and pain when applied immediately after surgery (20) . Additionally, application of a global, chronic SMF to pharmacologically induced synovitis demonstrated significant reduction in inflammatory infiltrate (44) . Investigation of the specific mechanisms governing SMF action has been limited, however the evidence suggests that the SMF may act via alterations in Ca2+ flux or other enzymatic reactions (23;28;29;36;40) . From these studies, the therapeutic application of magnetic fields for treatment of circulatory problems appears to be promising, but assessment of acute application of static magnetic fields in an injured, compromised tissue has not been investigated.
Initiation of acute inflammation, manifested as redness, heat, pain and swelling, occurs in response to mechanical injury, ionizing radiation or invading pathogens. Each of these stimuli can independently activate the release/formation of inflammatory mediators such as histamine, bradykinin, platelet activating factor (PAF), TNF-and prostaglandins from cells in the tissue.
These mediators act on endothelial cells to increase vascular permeability and cause vasodilation and relaxation of smooth muscle cells via production of nitric oxide (NO), and act on Ca2+ channels through endothelial dependent and independent processes (13) . As evidence suggests that SMF application can result in modulation of microvascular tone and flow, we hypothesize that acute application of SMF to an inflammatory injury may limit the formation of edema and therefore accelerate healing.
To test the hypothesis that locally applied acute static magnetic field exposure could significantly reduce edema formation and/or improve resolution, the hind-paw inflammation model was chosen. This model allowed for acute, localized application of static magnetic fields to an induced injury location and accurate quantification of the inflammatory response was facilitated by sequestration of inflammation to the paw itself. Two separate but related agents, -carrageenan (CA) and histamine, were chosen as severe and minor inflammatory stimuli, respectively, at the selected concentrations.
MATERIALS AND METHODS
All experiments were conducted in accordance with all rules and regulations set forth by the University of Virginia Animal Care and Use Committee.
Assessment of the efficacy of acute magnetic field exposure on edema formation and resolution was accomplished by utilizing a well established inflammatory model that has been used extensively for the detailed investigation of anti-inflammatory therapies. Inflammatory agents -carrageenan and histamine were injected locally in the paw of rats, alone or in conjunction with pharmacologic agents, resulting in a spatially and temporally defined inflammatory reaction. Magnetic field treatment was then applied locally to the inflamed paws at various strengths and durations in an attempt to elucidate the efficacy and/or mechanism(s) of static magnetic field action on induced edema.
The range of field strengths utilized in this study (7.5-400mT ) fall into the range generally advertised for magnetic field therapy products (10) and are on the same order of magnitude as those in other investigations into the efficacy of SMF treatment. The duration of exposure for the acute application was chosen based upon the generally accepted time scale for application of cryotherapy following injury (15-30 minutes) (8) together with the mid-range of previous studies (1-40 minutes). Direct comparison of the field strengths utilized in these studies with the field strength of products on the market is difficult due to the fact that most manufacturers report the strength at the core of their magnets and do not know what the "active" strength is at the target site. This may explain the widely varying experiences regarding efficacy reported in the community at large; many devices are designed in such a way that the distance from the core of the magnet to the target site is too great for any effective field strength to remain at the target site. To address this deficiency, the magnets utilized in this study were carefully calibrated so that the "actual" field strength to which the tissue was exposed was known , rather than estimated based on a stated core strength. Anesthesia was induced at a concentration of 2.5% isoflurane delivered in pure oxygen at a flow rate of 1.0 L/min via a VetEquip vaporizer (#911103, VetEquip Inc., Pleasanton, CA) and maintained for the duration of magnetic field exposure at a concentration of 1.5% and a flow rate of 1.0 L/min. During anesthesia, the animals were placed prone on a heating pad to maintain physiologic temperature of 37°C and the hindlimbs were loosely taped to a plexiglass stage to ensure reproducible orientation of the paw for treatment. The magnet treatment was applied within 30 seconds of injection via a lexan positioning device that placed the magnet directly over the injected paw, 2mm from the surface. Sham treated animals were injected with a vehicle control (saline or D.I. water) and subjected to identical immobilization and anesthesia treatment, the only difference being that no magnet was placed over the paw. At the conclusion of exposure, animals were removed from the isoflurane, awoke almost immediately, and were free to roam around their cage for the duration of the experiment. In an effort to address the apparent discrepancy in efficacy between the 15 and 30 minute magnet treatment on histamine-induced edema, a protocol was adopted that allowed for 
RESULTS

and 30 minute SMF application reduces histamine but not carrageenan induced edema
A 2 hour SMF application reduces carrageenan induced-edema
To address the differing efficacy of magnet application in preventing edema formation in CA vs. histamine-induced edema, the CA dose was reduced by half (0.1ml of 0.5% CA as opposed to 0.1ml of 1%) inducing an increase in volume proportional to that of histamine.
Application of the 70mT magnet for 15-minutes to this reduced magnitude CA-induced edema was not successful in significantly reducing the edema formation ( Figure 2F) . A shortened timeline with more frequent volume measurements was then adopted for an additional set of experiments to assess, with greater temporal resolution, the effect of magnet treatment on the edema formation with this reduced CA dose ( Figure 2G ). Again, no significant edema reduction was observed between sham and magnet treated paws. Finally, based on the previously presented data showing that application of the SMF for half the time to histamine-induced maximal edema (15 of the 30 minutes to max. edema formation) resulted in significant edema reduction, the SMF was applied for a 2-hour duration (2 of the 4 hours to max. CA-induced edema formation) to this reduced dose CA-induced edema. Interestingly, this 2 hour application resulted in a significant (33-37%) reduction in edema formation ( Figure 2H ).
SMF application is most effective when applied at the time of injury
Based on the data presented that a 15-minute magnet application is the most effective in reducing histamine-induced edema formation, investigation of the influence of magnetic field exposure on edema resolution was completed. Histamine treated animals were injected as previously described and the 70mT SMF was applied for 15 minutes at the time of maximal edema (30 minutes post-injection), resulting in no significant enhancement of edema resolution ( Figure 3A) . Furthermore, a 15-minute magnetic field pre-treatment applied just prior to histamine injection also resulted in no significant reduction in edema formation or resolution ( Figure 3B ).
SMF efficacy is dose dependent
To address whether the reduction in histamine-induced edema formation was dose dependent, a dose-response experiment was completed via application of a 400mT and 10mT in 
SMF application may act via L-type Ca2+ channels
After establishing that the magnetic field application can significantly reduce histamineinduced edema formation, investigation of the mechanism of action was attempted via administration of pharmacologic agents in conjunction with histamine stimulation and magnetic field exposure. Utilization of histamine as the injected inflammatory mediator, as opposed to CA, allows for very specific investigation of the early phase of the acute inflammatory response as the cascade of events is better defined and can be manipulated pharmacologically. (22) and administration of L-arginine (19) have also been shown to contribute to histamine-induced increased permeability (15) . While the histamine response is only one of the early phase mediators and therefore only one element of the acute inflammatory response per se, the isolation of this pathway minimizes the number of variables thus facilitating a more direct investigation of the mechanism(s) involved in magnet treatment.
Studies suggest that EMF exposure may activate NO production via activation of NOS Based on these findings, agonists of both nitric oxide synthesis and L-type calcium channel signaling were utilized in an effort to elucidate the mechanism by which SMF exposure significantly reduces induced edema. L-arginine, the substrate for nitric oxide synthesis, was coadministered sub-plantar with histamine (0.1ml) to potentiate edema formation as has been shown previously (9) . The 70mT magnetic field or sham was applied for 15 minutes and volumes were measured every 30 minutes for 3 hours ( Figure 5A ). Edema formation was significantly potentiated, 36-87%, by the co-administration of L-arginine + histamine + sham (closed squares, Figure 5A ) vs. histamine + sham treatment alone (closed circles, Figure 5A ).
This potentiation was suppressed 25-35% by application of the magnetic field (open squares, Figure 5A ), but the total volume level was not reduced to the level of histamine + magnet alone (open circles, Figure 5A ). Injection of L-arginine in de-ionized water did result in a measurable increase in paw volume and this can possibly be attributed to the potentiation of the small histamine release in response to the injection itself.
Concurrent administration of Ca2+ channel agonist BAY K8644 (34) 
DISCUSSION
This study demonstrates that SMF exposure significantly reduces induced edema in a time and dose dependent manner. Histamine-induced edema was significantly reduced by both a 15 and 30 minute SMF, whereas CA-induced edema required a 2 hour application to elicit a similar reduction. The effective dose duration appears to be related to the time to maximal edema formation. In the case of histamine-induced edema the maximally effective tested dose duration was 15 minutes, and in the CA-induced case it was 2 hours, both corresponding to 50% of the time to maximal edema formation; suggesting that the SMF must be applied for a sufficient fraction of the edema-formation period to have a significant effect. This finding is supported by two existing studies evaluating effects of a PEMF to CA-induced edema which reported a significant decrease in paw volume with an exposure time of 3-4 hours (25;48).
Additionally, we found that application of the field is required at the time of injury, as exposure before or after maximal edema formation yields no significant edema reduction.
It was also noted that the slopes of the recovery portion of the volume curves do not differ between sham and SMF treated groups and therefore it can be argued that the passive recoil of the tissue, lymphatic uptake, and venous reabsorption are not affected by the SMF application, as this would be manifested in a change in the rate of recovery. Taken together these results suggest that SMF treatment is not beneficial for the resolution of induced edema, but is useful in this model solely for the prevention of edema formation.
Whereas other studies have demonstrated physiological effects in tissues exposed to very high field strengths, on the order of 7-8T (9;16;35), it was found that a 400mT field did not have any influence on edema formation, suggesting that there may exist an upper limit of magnetic field strength that results in suppression of edema. The remaining two field strengths investigated, the 70mT field and 10mT field, were successful in reducing edema volume, but to different extents. The 70mT field reduced the edema formation to a greater degree than the 10mT field, but it was not 7 times more effective, suggesting that the response is non-linear and there may exist a saturation point, perhaps related to the available substrate for SMF action. Past studies have suggested that a lower limit of 1mT exists for eliciting a physiological affect from SMF application (21;46), but this is the first data suggesting a possible upper limit as well. The lower level may simply reflect the existence of a threshold level of activated substrate necessary to elicit a measurable response. The fact that the response is completely abolished above the yet to be determined upper threshold might also suggest that some other response is activated that masks the desired response. The mechanistic basis for the existence of such a "physiological window", however, requires further investigation.
Determination of potential mechanisms involved in the observed physiological responses to magnetic field exposure is ongoing, but no definitive mechanism or pathway has previously been identified. While studies have reported that magnetic field applications have decreased voltage-sensitive channel activation in GH3 cells (36) , increased second messenger levels in human skin fibroblasts (30) and FNC-B4 neuronal cells (31) , and increased microvessel dilation mediated by NO signaling (23), the results are mostly confounding as they are from different cell types in vitro and tissues in vivo with varying magnetic field dosages, durations and applied both locally and globally, thus complicating the assessment of therapeutic value. By locally applying the SMF in conjunction with pharmacological alteration of endothelial-dependent production of NO, or the Ca2+-induced contractile state in smooth muscle cells, we can begin to assess the mechanism(s) of SMF action and determine the validity of our hypotheses that SMF application might modulate the permeability and/or dilation resulting from histamine-induced edema.
Looking first at the results attained by agonizing NO production in conjunction with local SMF exposure, we find that although the magnitude of edema is elevated by increasing NO production, the degree of the edema reduction (the area encompassed between the magnet treated and sham curves, Figure 5A ) is not altered, suggesting that the magnet acts independently of NO production. Conversely, we find that by agonizing L-type Ca2+ channels, we eliminate the edema reduction evoked by application of the SMF. Taken 
